A Risk Assessment of Human Ether-a-Go-Go-Related Gene Potassium Channel Inhibition by Using Lipophilicity and Basicity for Drug Discovery
スポンサーリンク
概要
- 論文の詳細を見る
The blockade of human ether-a-go-go-related gene (hERG) potassium channels is widely regarded as the predominant cause of drug-induced QT prolongation. The correlation analysis between the inhibition of the hERG channel (hERG inhibition) and physicochemical properties was investigated by use of in-house quinolone antibiotics as model compounds. In order to establish a simple prediction model of hERG inhibition, we focused on the comprehensible physicochemical parameters such as lipophilicity (log P) and basicity (pKa). At first, the risk associated with increasing log P and pKa was examined by statistical analysis. It was demonstrated that the risk associated with increasing log P and pKa by one unit, respectively, almost identically increased. Consequently, equal attention should be paid to both parameters on hERG inhibition. Next, a prediction model of hERG inhibition which was represented by log P and pKa was investigated. As a result, we built the stepwise discriminant prediction model which took advantage of the risk judgment by zone classification. In conclusion, the impact of log P and pKa on hERG inhibition was clarified relatively and quantitatively. The quantitative risk assessment established based on both parameters, was considered to be a practical and useful tool in avoiding hERG inhibition and in the rational drug design for drug discovery, especially in lead optimization. Moreover, we also carried out a trend analysis using a different derivative and demonstrated that both parameters were equally significant for hERG inhibition.
- 公益社団法人 日本薬学会の論文
著者
-
Kawai Yukinori
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Akimoto Katsuya
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Takahashi Masayuki
Drug Delivery Research Center Developmental Research Laboratories Daiichi Pharmaceutical Co. Ltd.
-
Tsukamoto Shinsaku
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Ito Junko
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Ito Junko
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Kawai Yukinori
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Akimoto Katsuya
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
-
Tsukamoto Shinsaku
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
関連論文
- Investigation of the Intestinal Permeability and First-Pass Metabolism of Drugs in Cynomolgus Monkeys Using Single-Pass Intestinal Perfusion
- Evaluation of Serum Protein Binding by Using in Vitro Pharmacological Activity for the Effective Pharmacokinetics Profiling in Drug Discovery
- Photochemical Behavior of Sitafloxacin, Fluoroquinolone Antibiotic, in an Aqueous Solution
- Characteristics of Gastrointestinal Absorption of DX-9065a, a New Synthetic Anticoagulant
- 製剤研究におけるin silico研究の有用性と問題点
- Effect of Vehicles on Percutaneous Absorption of Bucladesine (Dibutyryl Cyclic AMP) in Normal and Damaged Rat Skin
- 11 ブクラデシン外用散剤の基礎的検討
- Photodecarboxylation of DX-9065a, a New Factor Xa Inhibitor, in Aqueous Solution
- Interaction of Quinolones with Metal Cations in Aqueous Solution
- A Novel Redox Reaction of Ebselen with Alcohol in Basic Solution
- A Risk Assessment of Human Ether-a-Go-Go-Related Gene Potassium Channel Inhibition by Using Lipophilicity and Basicity for Drug Discovery